Quick Answer
iSpecimen Inc. reported Cash and Equivalents of $1.88 million for fiscal year 2024.
iSpecimen Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $1.88M | -19.9% |
| 2023 | $2.34M | -84.7% |
| 2022 | $15.31M | -44.8% |
| 2021 | $27.74M | +3886.0% |
| 2020 | $695.9K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $1.75M | -35.6% | -18.6% |
| June 30, 2024 | $2.15M | +7.3% | +2.9% |
| March 31, 2024 | $2.09M | -44.5% | -10.8% |
| December 31, 2023 | $2.34M | -84.7% | -13.9% |
| September 30, 2023 | $2.72M | -86.8% | +35.8% |
| June 30, 2023 | $2.00M | -91.5% | -46.7% |
| March 31, 2023 | $3.76M | -85.6% | -75.4% |
| December 31, 2022 | $15.31M | -44.8% | -25.9% |
- iSpecimen Inc. showed a decrease of -19.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2024 period, iSpecimen Inc.’s cash and equivalents has grown by 169.9% (from $695.9 thousand to $1.88 million).
- The most recent figure is from iSpecimen Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 14, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: